Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany. **The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
View Top Employees from Aimmune TherapeuticsWebsite | http://www.aimmune.com |
Ticker | AIMT |
Revenue | $4 million |
Funding | $1 billion |
Employees | 318 (318 on RocketReach) |
Founded | 2011 |
Address | 8000 Marina Boulevard Suite 300, Brisbane, California 94005-1884, US |
Phone | (650) 614-5220 |
Fax | (650) 616-0075 |
Technologies |
JavaScript,
HTML,
reCAPTCHA
+26 more
(view full list)
|
Industry | Biotechnology, Drug Manufacturing & Research, Drug Discovery, Food Allergies, Pharmaceuticals, Desensitization, Healthcare, Oral Immunotherapy, Drug Development |
Web Rank | 3 Million |
Keywords | Biopharmaceuticals |
Competitors | DBV Technologies, Dynavax Technologies, NGM Biopharmaceuticals, Omeros Corporation, Sorrento Therapeutics, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Aimmune Therapeutics employee's phone or email?
The Aimmune Therapeutics annual revenue was $4 million in 2024.
Adrian Dana is the Vice President, Drug Safety and Pharmacovigilance of Aimmune Therapeutics.
318 people are employed at Aimmune Therapeutics.
Aimmune Therapeutics is based in Brisbane, California.
The NAICS codes for Aimmune Therapeutics are [3254, 325, 32541, 32].
The SIC codes for Aimmune Therapeutics are [28, 283].